Search Results for 'Hcv Hepatitis'

Boceprevir in Treatment Naive

• min-jolicoeur
• 7 Slides

SPRINT-2. Phase 3, Treatment . Naive. Treatment. ...

Sofosbuvir in Genotypes 2 or 3

• giovanna-bartolotta
• 9 Slides

VALENCE Trial. Phase . 3. Treatment. Naïve and ...

OBV/PTV/r

• conchita-marotz
• 5 Slides

OBV/PTV/r + RBV. Randomisation*. 1 : 1. Open labe...

LDV/SOF 90/400 mg

• aaron
• 4 Slides

qd. Non-randomised. Open-label. N =. 21. W12. SV...

Ehab Abd-El-Atty

• myesha-ticknor
• 39 Slides

Hepatitis-2015. Orlando, USA. July 20 - 22 2015...

Sofosbuvir + Peginterferon + Ribavirin in Genotype 2

• debby-jeon
• 10 Slides

. or 3 . LONESTAR-2. Phase 2. Treatment. . Exp...

Shruti H. Mehta, PhD MPH

• danika-pritchard
• 18 Slides

Associate Professor, Johns Hopkins Bloomberg Scho...

Peginterferon alfa-2a +

• stefany-barnette
• 8 Slides

RBV . versus. Interferon alfa. -. 2a + RBV . ACT...

ALLY-2

• tawny-fly
• 8 Slides

Design. Objective. SVR. 12. (HCV RNA < 25 IU/...

ALLY-2

• aaron
• 8 Slides

Design. Objective. SVR. 12. (HCV RNA < 25 IU/...

Sofosbuvir-Velpatasvir

• trish-goza
• 9 Slides

in Genotype 3. ASTRAL-3. Phase 3. . Treatment. ...

Sofosbuvir-Velpatasvir in Genotype 2

• stefany-barnette
• 0 Slides

ASTRAL-2*. Phase 3. . Treatment. . Naïve &...

Telaprevir

• karlyn-bohler
• 9 Slides

BID versus q8 in Treatment Naïve GT-1. OPTIMIZE ...

OBV/PTV/r DSV RBV OBV/PTV/r

• ellena-manuel
• 0 Slides

DSV . placebo. Randomisation*. Partial blind. 1...

Elbasvir Grazoprevir

• pamella-moone
• 0 Slides

Ribavirin in PI-experienced HCV GT1. C-SALVAGE...

ALLY-3 Design Objective SVR

• mitsue-stanley
• 0 Slides

12. (HCV RNA < 25 IU/ml), . with. 95% CI. DC...

www.hcvadvocate.org BLOG: hcvadvocate.blogspot.com

• luanne-stotts
• 0 Slides

. HCV Training Workshop. Version 19.0. HCSP/HCV ...

High HIV, HBV and HCV

• stefany-barnette
• 0 Slides

Prevalence. . among. . People. . Who. . Injec...

Listening to the service user voice:

• yoshiko-marsland
• 0 Slides

advantages for service delivery design . Magdale...

Ad Hoc Disease Transmission Advisory Committee (DTAC) Update

• alexa-scheidler
• 0 Slides

1. Spring 2018. Questions about reporting potenti...

Advances in the Treatment of

• danika-pritchard
• 0 Slides

HCV Genotype 3 and HIV/HCV Coinfection . What's S...

Ledipasvir-Sofosbuvir RBV in HCV GT 1,4 and Advanced Liver Disease

• alida-meadow
• 0 Slides

SOLAR-1 (Cohorts A and B). Phase . 2 . Treatment ...

PEG alfa-2a RBV versus

• alexa-scheidler
• 0 Slides

. PEG alfa-. 2a . versus. INF RBV . APRICOT S...

Generic treatments for HIV, HBV, HCV, TB could be mass produced for <$90 per patient

• min-jolicoeur
• 0 Slides

Dr Dzintars Gotham MBBS BSc(Hons). on behalf of. ...

Resistance to Direct Acting Antiviral Therapy

• tawny-fly
• 0 Slides

Resistance to HCV DAAs: What is the threat level...

Taking Steps to Improve the Management

• mitsue-stanley
• 0 Slides

of Chronic HCV. This educational program and spea...

HIV 2015-2016: New Agents, New Strategies

• ellena-manuel
• 0 Slides

Learning Objectives. EARLY VS DEFERRED ART. The C...

Community Pharmacy Considerations for HIV

• tawny-fly
• 0 Slides

& HCV . Therapy. Larry Pineda, . PharmD. , . ...

Daclatasvir Plus Sofosbuvir With or Without Ribavirin in Patients With HCV Genotype 3 Infection:

• kittie-lecroy
• 0 Slides

Interim Analysis of a French Multicenter Compassi...

Use the Web Browser on Your Mobile Device to Participate in Polling*

• phoebe-click
• 0 Slides

Go to: pollev.com/CCO2. or scan the QR code below...

July 2017 Lesson 1: Pregnant

• tatiana-dople
• 0 Slides

and . Postpartum Co-infected . Women . Core Compe...

Andrew I. Aronsohn, MD Associate Professor of Medicine

• alida-meadow
• 0 Slides

University of Chicago. Chicago, Illinois. Challen...

C-EDGE Co-Infected: Phase 3 Study of

• giovanna-bartolotta
• 27 Slides

C-EDGE Co-Infected: Phase 3 Study of Grazoprevi...

Jennifer Layden, MD, PhD

• olivia-moreira
• 18 Slides

Jennifer Layden, MD, PhD Assistant Professor of M...

Dose adjustment for organ dysfunction

• yoshiko-marsland
• 52 Slides

By : . Manal. . Mostafa. . Saleh. Demonstrator ...

Kroonilist viirusvastast ravi saavate patsientide probleemid hambaravis

• 2coolprecise
• 17 Slides

Anna Strezeva. Anna Vesselova. Sissejuhatus. Kroon...

• shoulderheinz
• 19 Slides

Viral Hepatitis Clinical Research Program. The Kir...

Telaprevir BID versus q8 in Treatment Naïve GT-1

• volatilenestle
• 9 Slides

OPTIMIZE (. Study . C211). Phase . 3. Treatment. ...

HACA INCOME LIMITS HOUSING CHOICE VOUCHER (HCV) & PROJECT-BASED VOUCH

• jubilantbikers
• 1 Slides

Public Housing 1 $27,450 $45,700 $73,100 2 $31,3...

This product is intended to be used to guide the selection of treatmen

• rosemary
• 4 Slides

siemens.com/molecular Optimize Treatment Decisions...